News

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the treatment of…
Read More...

CStone Pharmaceuticals and Pfizer Investment Co. Ltd. and Pfizer Corporation Hong Kong Limited announced today the formation of a strategic collaboration that encompasses a $200 million…
Read More...

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and Arbor Biotechnologies, an early-stage life sciences company,…
Read More...

Orgenesis Inc. and Koligo Therapeutics, Inc. announced that the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected…
Read More...

FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs, is pleased to announce it has entered into a manufacturing agreement with…
Read More...

AVROBIO, Inc. announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher…
Read More...

XtalPi, an Artificial Intelligence (AI) drug discovery and development technology company, announces an oversubscribed Series C funding of $318.8 million co-led by SoftBank Vision Fund…
Read More...

Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older…
Read More...

GlaxoSmithKline plc (GSK) announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and…
Read More...

Gilead Sciences, Inc. and Eisai Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of…
Read More...

AbCellera and IGM Biosciences, Inc. announced that they have entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery…
Read More...

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, and the US Army Medical Research and Development Command (USAMRDC),…
Read More...

Millendo Therapeutics, Inc. a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced…
Read More...

The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and ChemRar Group have agreed to supply Avifavir, the world's first registered favipiravir-based drug against…
Read More...

Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According…
Read More...

Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT)…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI…
Read More...

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess…
Read More...

InSysBio announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the…
Read More...

Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical…
Read More...